![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/NEULANDLAB.png)
Share the post "Neuland Laboratories ‘s Q3 2024-25 Latest News: Profit Grows by 24.82% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 1.32 % in the past year, substantial increase in net sales/revenue by 28.05 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 2740.74 %. Marginal increase in other income during this quarter, up by 1277.75%. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Neuland Laboratories Limited. Notable increase of 24.82 % in net profit Year to Year, Neuland Laboratories Limited’s profitability increased by 209.31 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 24.81 % Year to Year. EPS increased by 209.3 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 392.828 Cr | Rs. 310.844 Cr | Rs. 398.032 Cr | + 28.05 % | + 1.32 % |
| Expenses | Rs. 271.56 Cr | Rs. 248.62 Cr | Rs. 311.43 Cr | + 25.26 % | + 14.68 % |
| Operating Profit | Rs. 121.27 Cr | Rs. 62.22 Cr | Rs. 86.6 Cr | + 39.18 % | -28.59 % |
| OPM % | 30.87 % | 20.02 % | 21.76 % | + 1.74 % | -9.11 % |
| Other Income | Rs. 2.101 Cr | Rs. 4.332 Cr | Rs. 59.684 Cr | + 1277.75 % | + 2740.74 % |
| Interest | Rs. 3.74 Cr | Rs. 1.06 Cr | Rs. 2.22 Cr | + 109.43 % | -40.64 % |
| Depreciation | Rs. 15.14 Cr | Rs. 16.08 Cr | Rs. 16.3 Cr | + 1.37 % | + 7.66 % |
| Profit before tax | Rs. 104.49 Cr | Rs. 49.41 Cr | Rs. 127.76 Cr | + 158.57 % | + 22.27 % |
| Tax % | 22.1 % | 33.55 % | 20.49 % | -13.06 % | -1.61 % |
| Net Profit | Rs. 81.39 Cr | Rs. 32.84 Cr | Rs. 101.59 Cr | + 209.35 % | + 24.82 % |
| EPS in Rs | Rs. 63.44 | Rs. 25.6 | Rs. 79.18 | + 209.3 % | + 24.81 % |
Today, we’re looking at Neuland Laboratories Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 1.32 %. However, it did see a marginal increase of 28.05 % from the previous quarter. Expenses ticked up slightly by 25.26 % quarter-on-quarter, aligning with the annual rise of 14.68 %. Operating profit, while down -28.59 % compared to last year, faced a quarter-on-quarter increase of 39.18 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -9.11 %, but an expansion of 1.74 % sequentially. Other income rose by 1277.75 % compared to the last quarter, despite an annual growth of 2740.74 %. Interest expenses surged remarkably by 109.43 % from the previous quarter, yet the year-over-year decrease remains at a moderate -40.64 %. Depreciation costs climbed by 1.37 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 7.66 %. Profit before tax grew annually by 22.27 % but saw an increase from the preceding quarter by 158.57 %.
Tax expenses as a percentage of profits decreased slightly by -1.61 % compared to last year, with a more notable quarter-on-quarter decrease of -13.06 %. Net profit rose by 24.82 % year-on-year but experienced a 209.35 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 24.81 % but a quarterly rise of 209.3 %. In summary, Neuland Laboratories Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 392.828 Cr | Rs. 310.844 Cr | Rs. 398.032 Cr | + 28.05 % | + 1.32 % |
| Expenses | Rs. 271.56 Cr | Rs. 248.62 Cr | Rs. 311.43 Cr | + 25.26 % | + 14.68 % |
| Operating Profit | Rs. 121.27 Cr | Rs. 62.22 Cr | Rs. 86.6 Cr | + 39.18 % | -28.59 % |
| Net Profit | Rs. 81.39 Cr | Rs. 32.84 Cr | Rs. 101.59 Cr | + 209.35 % | + 24.82 % |
| EPS in Rs | Rs. 63.44 | Rs. 25.6 | Rs. 79.18 | + 209.3 % | + 24.81 % |
In reviewing Neuland Laboratories Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 1.32 % year-on-year growth, however, there was a minor increase of 28.05 % from the previous quarter. Expenses rose by 14.68 % compared to the previous year, with a 25.26 % increase quarter-on-quarter. Operating Profit dropped by -28.59 % annually, and saw a 39.18 % increase from the last quarter.
Net Profit showed yearly increase of 24.82 %, and experienced a 209.35 % increase from the previous quarter. Earnings Per Share (EPS) rose by 24.81 % annually, however rose by 209.3 % compared to the last quarter. In essence, while Neuland Laboratories Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/NRBBEARING.png)
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/MOHITPPR.png)